分享产品介绍 评论(0)
分子别名
ABBV-085, PR-1498487-MMAE, PR-1498487, Samrotamab vedotin表达宿主
CHO分子量
23-25kDa&47-53kDa (Reducing)
纯度
＞95% by SDS-PAGE内毒素含量
<0.1EU/μg活性
Immobilized LRRC15/LIB His Tag, Human (Cat. No. UA010915) at 10.0μg/mL (100μL/well) can bind Samrotamab (Cat. No. UA011138) with EC50 of 6.86-9.73ng/mL.标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
PBS, PH7.4, 5% trehalose
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1.Galvan M, Boer R, Schudt C. Interaction of telenzepine with muscarinic receptors in mammalian sympathetic ganglia. Eur J Pharmacol. 1989 Aug 11;167(1):1-10.
Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin). It is a humanized IgG1-κ chimeric antibody targeting LRRC15.
电泳
1μg (R: reducing condition, N: non-reducing condition).
ELISA
Immobilized LRRC15/LIB His Tag, Human (Cat. No. UA010915) at 10.0μg/mL (100μL/well) can bind Samrotamab (Cat. No. UA011138) with EC50 of 6.86-9.73ng/mL.
评论(0)